189 related articles for article (PubMed ID: 25041998)
1. Suppression in mice of immunosurveillance against PEGylated liposomes by encapsulated doxorubicin.
Yahuafai J; Asai T; Nakamura G; Fukuta T; Siripong P; Hyodo K; Ishihara H; Kikuchi H; Oku N
J Control Release; 2014 Oct; 192():167-73. PubMed ID: 25041998
[TBL] [Abstract][Full Text] [Related]
2. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.
Koide H; Asai T; Hatanaka K; Akai S; Ishii T; Kenjo E; Ishida T; Kiwada H; Tsukada H; Oku N
Int J Pharm; 2010 Jun; 392(1-2):218-23. PubMed ID: 20227473
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
[TBL] [Abstract][Full Text] [Related]
4. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
6. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
7. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
8. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
9. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
10. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid.
Wang S; Xu H; Xu J; Zhang Y; Liu Y; Deng YH; Chen D
AAPS PharmSciTech; 2010 Jun; 11(2):870-7. PubMed ID: 20490957
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection.
Laverman P; Carstens MG; Boerman OC; Dams ET; Oyen WJ; van Rooijen N; Corstens FH; Storm G
J Pharmacol Exp Ther; 2001 Aug; 298(2):607-12. PubMed ID: 11454922
[TBL] [Abstract][Full Text] [Related]
12. Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery.
Scomparin A; Salmaso S; Bersani S; Satchi-Fainaro R; Caliceti P
Eur J Pharm Sci; 2011 Apr; 42(5):547-58. PubMed ID: 21371555
[TBL] [Abstract][Full Text] [Related]
13. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
[TBL] [Abstract][Full Text] [Related]
15. Suppression of immune response by antigen-modified liposomes encapsulating model agents: a novel strategy for the treatment of allergy.
Ichikawa K; Asai T; Shimizu K; Yonezawa S; Urakami T; Miyauchi H; Kawashima H; Ishida T; Kiwada H; Oku N
J Control Release; 2013 May; 167(3):284-9. PubMed ID: 23419947
[TBL] [Abstract][Full Text] [Related]
16. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
17. Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU).
Park SM; Kim MS; Park SJ; Park ES; Choi KS; Kim YS; Kim HR
J Control Release; 2013 Sep; 170(3):373-9. PubMed ID: 23770213
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of antitumor effect of doxorubicin by its complexation with gamma-cyclodextrin in pegylated liposomes.
Arima H; Hagiwara Y; Hirayama F; Uekama K
J Drug Target; 2006 May; 14(4):225-32. PubMed ID: 16777681
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts.
Sakakibara T; Chen FA; Kida H; Kunieda K; Cuenca RE; Martin FJ; Bankert RB
Cancer Res; 1996 Aug; 56(16):3743-6. PubMed ID: 8706018
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D
Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
